Barclays has reiterated its 'overweight' to high conviction recommendation on Fresenius, while adjusting its price target from 36 to 36.5 euros, following an investor day (CMD) of the German healthcare services group.

"We came away from this meeting with additional positive points, and raised our figures on the improved outlook for Helios and a business update from Kabi", says the broker.

Barclays sees 'upside risk', now above the EBIT growth target, and considers that 'management's greater confidence in the business is more indicative of the significant change within the company'.

Copyright (c) 2024 All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.